Inhaled Insulin: Being First Isn't Necessarily Best
Executive Summary
The early bird may get the worm, but it's the second mouse that finds the cheese. This has proven true many times in the drug industry in the past. It may prove true once again with inhaled insulin.
You may also be interested in...
Insulin Delivery: Still Waiting to Exhale
After the commercial failure of Exubera, is inhaled insulin dead? Not at all. Exubera failed for very specific reasons: a cumbersome device, non-standard dosing, and no real clinical utility. The Exubera snafu has eroded the commercial value of inhaled insulin, but Nektar may be the best-positioned company currently competing in the inhaled insulin space. Nektar can afford to re-partner its version for less, because Pfizer has already paid for the bulk of the drug development work.
Exubera's Problem: It's Still Just Insulin
Exubera's shaky start isn't that surprising. Pfizer is new to the large molecule game, Exubera's a first of its kind, and, it seems, injections aren't so much the problem as insulin itself.
Exubera's Problem: It's Still Just Insulin
Exubera's shaky start isn't that surprising. Pfizer is new to the large molecule game, Exubera's a first of its kind, and, it seems, injections aren't so much the problem as insulin itself.